211 related articles for article (PubMed ID: 25070434)
1. Five-year experience of organized colorectal cancer screening in a Swedish population - increased compliance with age, female gender, and subsequent screening round.
Blom J; Kilpeläinen S; Hultcrantz R; Törnberg S
J Med Screen; 2014 Sep; 21(3):144-50. PubMed ID: 25070434
[TBL] [Abstract][Full Text] [Related]
2. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
3. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
[TBL] [Abstract][Full Text] [Related]
4. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
5. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
[TBL] [Abstract][Full Text] [Related]
7. Early detection of colorectal cancer with faecal occult blood test screening.
Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
[TBL] [Abstract][Full Text] [Related]
8. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
[TBL] [Abstract][Full Text] [Related]
9. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.
Kershenbaum A; Flugelman A; Lejbkowicz F; Arad H; Rennert G
Eur J Cancer; 2013 Mar; 49(4):923-30. PubMed ID: 23099005
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
11. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
[TBL] [Abstract][Full Text] [Related]
13. A comparison of different strategies used to invite subjects with a positive faecal occult blood test to a colonoscopy assessment. A randomised controlled trial in population-based screening programmes.
Zorzi M; Giorgi Rossi P; Cogo C; Falcini F; Giorgi D; Grazzini G; Mariotti L; Matarese V; Soppelsa F; Senore C; Ferro A;
Prev Med; 2014 Aug; 65():70-6. PubMed ID: 24811759
[TBL] [Abstract][Full Text] [Related]
14. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
[TBL] [Abstract][Full Text] [Related]
15. [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies].
Pippa G; Ferrara M; Valle S; Diego B; Alessandra B; Apuzzo M; Bazuro ME; Tammaro G; Federici A
Recenti Prog Med; 2009; 100(7-8):348-51. PubMed ID: 19725474
[TBL] [Abstract][Full Text] [Related]
16. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
Malila N; Oivanen T; Hakama M
Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer screening in LHU4 Chiavarese, Italy: ethical, methodological and outcome evaluations at the end of the first round.
Ferrari Bravo M; De Conca V; Devoto GL; Sironi M; Mele R; Fumagalli A; Rimassa P; Rossi G; Zampogna A; Sticchi C; Gabutti G;
J Prev Med Hyg; 2012 Mar; 53(1):37-43. PubMed ID: 22803318
[TBL] [Abstract][Full Text] [Related]
18. Mass screening for colorectal cancer: compliance in Almopea Region.
Chrissidis T; Saliangas K; Economou A; Nikoloudis N; Andreadis E; Prodromou K; Georgakis K
Tech Coloproctol; 2004 Nov; 8 Suppl 1():s193-5. PubMed ID: 15655620
[TBL] [Abstract][Full Text] [Related]
19. Attendance and yield over three rounds of population-based fecal immunochemical test screening.
Kapidzic A; Grobbee EJ; Hol L; van Roon AH; van Vuuren AJ; Spijker W; Izelaar K; van Ballegooijen M; Kuipers EJ; van Leerdam ME
Am J Gastroenterol; 2014 Aug; 109(8):1257-64. PubMed ID: 24980879
[TBL] [Abstract][Full Text] [Related]
20. A population-based, community estimate of total colon examination: the impact on compliance with screening for colorectal cancer.
Schoen RE; Weissfeld JL; Trauth JM; Ling BS; Hayran M
Am J Gastroenterol; 2002 Feb; 97(2):446-51. PubMed ID: 11866286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
